Show simple document record

dc.contributor.advisorRancourt, Claudinefr
dc.contributor.authorShao, Huifr
dc.date.accessioned2014-05-15T18:37:33Z
dc.date.available2014-05-15T18:37:33Z
dc.date.created2002fr
dc.date.issued2002fr
dc.identifier.isbn0612745368fr
dc.identifier.urihttp://savoirs.usherbrooke.ca/handle/11143/3297
dc.description.abstractOvarian cancer is the leading cause of death from gynecological cancers in Western countries. Over 70% of the patients present with late stage disease, the five-year survival rate for these patients remains at best of 15-30%. Tumor antigen CA125 expression has been shown to correlate with the clinical course of the disease, and CA125 is currently used as a predictor of clinical recurrence in ovarian cancer and to monitor response to chemotherapy treatment. Previous studies showed that CA125 is a high molecular weight glycoprotein having properties of a mucin-type molecule. The biochemical and molecular nature and the function of this antigen are poorly understood. In this study, we have developed an approach based upon intracellular expression of single-chain antibodies (ScFvs) to achieve selective abrogation of CA125, thus to study the role of CA125 in human ovarian cancer cells. The study shows that a ScFv against the CA125 antigen was constructed, and that the soluble antibodies bind to CA125 protein in ELISA when expressed in E.coli."--Résumé abrégé par UMIfr
dc.language.isoengfr
dc.publisherUniversité de Sherbrookefr
dc.rights© Hui Shaofr
dc.titleConstruction and characterization of OC125 single-chain antibodyfr
dc.typeMémoirefr
tme.degree.disciplineMicrobiologiefr
tme.degree.grantorFaculté de médecine et des sciences de la santéfr
tme.degree.levelMaîtrisefr
tme.degree.nameM. Sc.fr


Files in this document

Thumbnail

This document appears in the following Collection(s)

Show simple document record